At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 501 enrolled
Drug / intervention
pregabalin (Lyrica) +2 moredrug
Likely dose
pregabalin (Lyrica) 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple Dose, Randomized, Double-Blind Multicenter Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Treatment Of Patients With Post-Surgical Pain From Hysterectomy
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted May 3, 2007·Updated Feb 10, 2021
In Brief
A Phase 3 clinical trial evaluating pregabalin (Lyrica) and matched placebo for Pain, Postoperative. Completed, enrolled 501 participants across 42 sites in 9 countries.
Detailed Summary
To assess the efficacy of pregabalin compared to placebo on pain following hysterectomy , measured using subject reported assessments of pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Postoperative
CountriesCanada, Czechia, Hong Kong, South Africa, Spain, Sweden, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartJun 2007
Primary CompletionMay 2010
Study CompletionOct 2010
TodayJul 2026
First PostedMay 3, 2007
Enrollment StartJun 1, 2007
Primary CompletionMay 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 19.2 years ago
Interventions
pregabalin (Lyrica)drug
150 mg/day double blind (divided doses)
pregabalin (Lyrica)drug
300 mg/day double blind (divided doses)
matched placebodrug
matched placebo